EN DE
Watch Amicogen Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Amicogen Inc (092040) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of Amicogen Inc stock KRW 969, price KRW 929, upside +4.3%, quality 25 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7092040005

AI Amicogen Inc logo Thin data Nov 18, 2026

Amicogen Inc

092040 · KQ

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Revenue last quarter +32% vs. a year ago. 
Fair value 969.07 KRW · Fairly valued 
Moderate debt 
Mixed vs. peers (4/10) 
Quality 25/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −18.4 %/yr in KRW) 
Loss-making · -41.3% net margin (TTM) 
Negative free cash flow 
Narrow moat 5/100
Thin data 
Estimate
Watch Amicogen Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

20,964 KRW 822.00 KRW Fair Value 969.07 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 18, 2026.

How to read this chart

60‑month range 822.00 KRW – 20,964 KRW · fair‑value band 726.80 KRW – 1,211 KRW · the 929.00 KRW price screens below the 969.07 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 18, 2026.

Follow Amicogen in your weekly email

Every Wednesday you see whether Amicogen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food.

Show moreShow less

It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products.

In addition, the company offers oral incurable and rare disease treatments, as well as manufactures and sells of pharmaceutical raw materials, animal drugs, human drugs, etc. The company was incorporated in 2000 and is headquartered in Jinju-Si, South Korea.

Stock analysis

Amicogen Inc (092040) currently trades at 929.00 KRW, while our estimate is 969.07 KRW, so the stock looks roughly fairly valued today (gap 4.1%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 726.80 KRW (bear) to 1,211 KRW (bull), the price of 929.00 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Amicogen Inc reported revenue of 42.0B KRW in FY2025 versus 125B KRW in FY2021, a compound −23.9%/yr. Reported net income was −30.0B KRW in FY2025.

Key figures

Market cap 65.2B KRW (≈ $48.9M) Micro · P/S ratio 1.50 · EPS (TTM) −273.85 KRW · Net margin −41.3% · Return on equity −16.8% · Return on assets (EBIT) −2.9% (5-year average) · Operating margin −30.1% · Revenue (TTM) 46.7B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 69% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 4%, 092040 screens cheaper than that median.

Fair Value

Bear 726.80 KRW Fair Value 969.07 KRW Bull 1,211 KRW
Price 929.00 KRW · Upside +4.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 29
Debt, balance sheet and risk of trouble
Investment 87
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 36
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−75.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−33.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.4%
Start year 2020 (pandemic). Over 10 years: +2.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.4% (2020) → −36.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 092040, get fair value alerts →

Compare Amicogen Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside +4.3% · Above median
Profitability
Return on assets −12.9% · Bottom 25%
Net margin (12 months) −41.3% · Bottom 25%
Operating margin (12 months) −30.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 32.0% · Top 25%
Balance sheet
Debt / equity 0.57× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.69× · Cheapest 25%
P/S (12 months) 1.40× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)39 · sector 19
FUTURE (revenue growth)100 · sector 28
PAST (return on equity)0 · sector 26
HEALTH (low debt)72 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.48 $113.53 +36% vs 092040
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.90 ¥52.43 +12% vs 092040
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,872 ₹1,983 +6% vs 092040
Haleon plc HLN $9.05 $8.47 −6% vs 092040
Merck KGaA MRK €149.50 €108.83 −27% vs 092040
Galderma Group GALD CHF 187.55 CHF 112.46 −40% vs 092040
Takeda Pharmaceutical Company TAK $21.64 $11.23 −48% vs 092040
Sandoz Group SDZ CHF 81.50 CHF 40.91 −50% vs 092040
Teva Pharmaceutical Industries Limited TEVA $42.62 $20.74 −51% vs 092040
Divi's Laboratories Limited DIVISLAB ₹11,049 ₹1,567 −86% vs 092040

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Amicogen Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Amicogen Inc Fair Value". https://www.fairvalue-calculator.com/stock/092040

Frequently asked questions

Is Amicogen Inc (092040) overvalued or undervalued?
As of Nov 18, 2026, our estimate of fair value is 969.07 KRW versus a price of 929.00 KRW, about +4% upside (fairly valued).
What is the fair value of 092040?
Our estimate for Amicogen Inc is 969.07 KRW (as of Nov 18, 2026), built from audited fundamentals. The current price: 929.00 KRW.
What is the quality score of 092040?
Amicogen Inc has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Amicogen Inc (092040)?
Our calculated price target is the estimate of 969.07 KRW (as of Nov 18, 2026). Cautious scenario 726.80 KRW, optimistic scenario 1,211 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Amicogen Inc stock forecast for 2026?
Our estimate puts fair value at 969.07 KRW, about +4% upside versus a price of 929.00 KRW (fairly valued). Cautious scenario 726.80 KRW, optimistic scenario 1,211 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Amicogen Inc (092040)?
Amicogen Inc reported trailing-twelve-month revenue of about 46.7B KRW (latest available figure, as of Nov 18, 2026).
What is the intrinsic value of Amicogen Inc (092040)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Amicogen Inc it is 969.07 KRW per share (as of Nov 18, 2026), against a price of 929.00 KRW.
Is Amicogen Inc stock overvalued or undervalued in 2026?
As of Nov 18, 2026, 092040 trades below its calculated fair value: price 929.00 KRW, fair value 969.07 KRW, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 092040?
No. The price is what the market pays today (929.00 KRW); the fair value is what the company's own numbers justify (969.07 KRW). For Amicogen Inc the two are 40.07 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Amicogen Inc worth?
The market values Amicogen Inc at about 65.2B KRW (market capitalisation, as of Nov 18, 2026). Per share that is 929.00 KRW; our models calculate a fair value of 969.07 KRW per share.
What do the bullish and bearish scenarios say about 092040?
Our models span a range for Amicogen Inc: cautious scenario 726.80 KRW, base 969.07 KRW, optimistic 1,211 KRW per share (as of Nov 18, 2026, price 929.00 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Amicogen Inc (092040)?
Balance-sheet figures for Amicogen Inc (as of Nov 18, 2026): return on equity −16.8%, debt of 0.57 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is 092040 from its 52-week high?
Amicogen Inc trades at 929.00 KRW, about 69% below its 52-week high of 3,005 KRW and 13% above the low of 822.00 KRW (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of 969.07 KRW is for.
Which stocks are comparable to Amicogen Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Amicogen Inc stock attractive at the current price?
The data as of Nov 18, 2026: price 929.00 KRW, calculated fair value 969.07 KRW (+4%), Quality Score 25/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. Amicogen Inc currently trades 4% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Amicogen Inc (092040)?
The closing price on Nov 18, 2026 was 929.00 KRW. Our estimate is 969.07 KRW, about +4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Amicogen Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Amicogen Inc

How large is the market capitalisation of Amicogen Inc (092040)?
The market capitalisation of Amicogen Inc is 65.2B KRW (≈ $48.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Amicogen Inc (092040)?
The price-to-sales ratio of Amicogen Inc is 1.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Amicogen Inc (092040)?
Earnings per share at Amicogen Inc are −273.85 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Amicogen Inc (092040)?
The net margin of Amicogen Inc is −41.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Amicogen Inc (092040)?
The return on equity (ROE) of Amicogen Inc is −16.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Amicogen Inc (092040)?
On an EBIT basis the return on assets of Amicogen Inc is −2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Amicogen Inc (092040)?
The operating margin of Amicogen Inc is −30.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Amicogen Inc (092040)?
Revenue at Amicogen Inc is growing 32.0% versus a year earlier (3y avg −33.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Amicogen Inc (092040)?
Earnings per share at Amicogen Inc are down 16.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Amicogen Inc (092040) generate?
The free cash flow of Amicogen Inc is −28.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Amicogen Inc (092040) carry?
The net debt of Amicogen Inc is 86.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Amicogen Inc in the live analysis

One click puts Amicogen Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.